Norge -
norsk -
Statens legemiddelverk
midazolam medical valley 7.5 mg
medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 7.5 mg
Norge -
norsk -
Statens legemiddelverk
midazolam medical valley 10 mg
medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 10 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 50 mg
2care4 aps - lisdeksamfetamindimesilat - kapsel, hard - 50 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 70 mg
2care4 aps - lisdeksamfetamindimesilat - kapsel, hard - 70 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 30 mg
2care4 aps - lisdeksamfetamindimesilat - kapsel, hard - 30 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 20 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 20 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 40 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 40 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 60 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 60 mg
Norge -
norsk -
Statens legemiddelverk
dormaquin vet 5 mg/ ml
dechra regulatory b.v. - midazolam - injeksjonsvæske, oppløsning - 5 mg/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).